Delayed
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
26.62
USD
|
-0.86%
|
|
-2.38%
|
-5.23%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
19,426
|
17,116
|
17,432
|
12,497
|
12,005
|
-
|
-
|
Enterprise Value (EV)
1 |
23,181
|
22,089
|
22,814
|
18,155
|
17,782
|
18,044
|
17,850
|
P/E ratio
|
31.2
x
|
39
x
|
558
x
|
11.1
x
|
12.6
x
|
10.8
x
|
9.12
x
|
Yield
|
0.6%
|
1.71%
|
1.92%
|
2.85%
|
3.38%
|
3.67%
|
3.88%
|
Capitalization / Revenue
|
9.15
x
|
7.48
x
|
7.79
x
|
5.31
x
|
4.53
x
|
4.11
x
|
3.77
x
|
EV / Revenue
|
10.9
x
|
9.65
x
|
10.2
x
|
7.71
x
|
6.71
x
|
6.17
x
|
5.6
x
|
EV / EBITDA
|
14.3
x
|
11.4
x
|
8.89
x
|
6.47
x
|
7.14
x
|
6.6
x
|
6.05
x
|
EV / FCF
|
11.4
x
|
12.5
x
|
10.2
x
|
6.7
x
|
18.8
x
|
14.4
x
|
12.1
x
|
FCF Yield
|
8.78%
|
8%
|
9.8%
|
14.9%
|
5.33%
|
6.94%
|
8.26%
|
Price to Book
|
3.07
x
|
2.36
x
|
2.52
x
|
1.66
x
|
1.49
x
|
0.96
x
|
0.81
x
|
Nbr of stocks (in thousands)
|
388,132
|
429,511
|
441,104
|
444,886
|
450,981
|
-
|
-
|
Reference price
2 |
50.05
|
39.85
|
39.52
|
28.09
|
26.62
|
26.62
|
26.62
|
Announcement Date
|
2/17/21
|
2/15/22
|
2/15/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,122
|
2,289
|
2,237
|
2,355
|
2,651
|
2,923
|
3,188
|
EBITDA
1 |
1,621
|
1,944
|
2,566
|
2,806
|
2,492
|
2,732
|
2,951
|
EBIT
1 |
1,598
|
1,921
|
2,560
|
2,806
|
2,111
|
2,384
|
2,831
|
Operating Margin
|
75.31%
|
83.92%
|
114.44%
|
119.14%
|
79.61%
|
81.58%
|
88.82%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
230
|
1,700
|
1,411
|
1,468
|
-
|
Net income
1 |
975
|
620
|
43
|
1,135
|
941.8
|
1,097
|
1,274
|
Net margin
|
45.95%
|
27.09%
|
1.92%
|
48.2%
|
35.52%
|
37.52%
|
39.97%
|
EPS
2 |
1.606
|
1.021
|
0.0708
|
2.530
|
2.105
|
2.475
|
2.920
|
Free Cash Flow
1 |
2,035
|
1,767
|
2,235
|
2,708
|
947
|
1,253
|
1,475
|
FCF margin
|
95.88%
|
77.18%
|
99.92%
|
115%
|
35.72%
|
42.87%
|
46.27%
|
FCF Conversion (EBITDA)
|
125.52%
|
90.88%
|
87.11%
|
96.51%
|
38%
|
45.86%
|
49.97%
|
FCF Conversion (Net income)
|
208.68%
|
284.94%
|
5,198.2%
|
238.6%
|
100.56%
|
114.25%
|
115.78%
|
Dividend per Share
2 |
0.3000
|
0.6800
|
0.7600
|
0.8000
|
0.9006
|
0.9760
|
1.033
|
Announcement Date
|
2/17/21
|
2/15/22
|
2/15/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
576
|
562
|
536
|
573
|
566
|
684
|
538
|
536.3
|
596
|
568
|
603.2
|
683
|
713.6
|
-
|
-
|
EBITDA
1 |
494
|
556
|
480
|
548
|
983
|
1,044
|
498
|
582.2
|
682
|
656
|
592
|
651.7
|
625.1
|
701
|
640
|
EBIT
1 |
488
|
550
|
480
|
548
|
983
|
1,044
|
498
|
582.2
|
681.7
|
656
|
396.2
|
403.8
|
867.8
|
-
|
-
|
Operating Margin
|
84.72%
|
97.86%
|
89.55%
|
95.64%
|
173.67%
|
152.63%
|
92.57%
|
108.56%
|
114.38%
|
115.49%
|
65.67%
|
59.12%
|
121.61%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
8
|
52
|
305
|
143
|
-456
|
-
|
-
|
-
|
494
|
5
|
56.9
|
35.53
|
816.6
|
-
|
-
|
Net margin
|
1.39%
|
9.25%
|
56.9%
|
24.96%
|
-80.57%
|
-
|
-
|
-
|
82.89%
|
0.88%
|
9.43%
|
5.2%
|
114.42%
|
-
|
-
|
EPS
2 |
0.0132
|
0.0857
|
0.5025
|
0.2360
|
-0.7512
|
-
|
-
|
-
|
1.100
|
0.0100
|
0.1300
|
0.0800
|
1.820
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.1900
|
0.1900
|
0.1900
|
0.2000
|
0.2000
|
0.2000
|
0.2000
|
0.2000
|
0.2100
|
0.2100
|
0.2079
|
-
|
-
|
Announcement Date
|
2/15/22
|
5/5/22
|
8/4/22
|
11/8/22
|
2/15/23
|
5/9/23
|
8/8/23
|
11/8/23
|
2/15/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
3,755
|
4,973
|
5,381
|
5,658
|
5,777
|
6,039
|
5,845
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.316
x
|
2.558
x
|
2.097
x
|
2.016
x
|
2.318
x
|
2.211
x
|
1.98
x
|
Free Cash Flow
1 |
2,035
|
1,767
|
2,235
|
2,708
|
947
|
1,253
|
1,475
|
ROE (net income / shareholders' equity)
|
18.5%
|
17.5%
|
28.2%
|
43.5%
|
29.8%
|
24.5%
|
22.6%
|
ROA (Net income/ Total Assets)
|
10.4%
|
10.5%
|
13%
|
15.9%
|
9.67%
|
9.71%
|
9.34%
|
Assets
1 |
9,359
|
5,884
|
330.2
|
7,130
|
9,743
|
11,291
|
13,645
|
Book Value Per Share
2 |
16.30
|
16.90
|
15.70
|
16.90
|
17.90
|
27.70
|
33.00
|
Cash Flow per Share
2 |
5.420
|
3.320
|
3.530
|
4.960
|
4.140
|
4.290
|
-
|
Capex
1 |
-
|
2,192
|
1,742
|
2,116
|
1,500
|
1,500
|
1,500
|
Capex / Sales
|
-
|
95.74%
|
77.86%
|
89.85%
|
56.57%
|
51.32%
|
47.06%
|
Announcement Date
|
2/17/21
|
2/15/22
|
2/15/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
26.62
USD Average target price
45.75
USD Spread / Average Target +71.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.23% | 12.01B | | +38.51% | 727B | | +31.74% | 599B | | -6.23% | 354B | | +18.78% | 328B | | +1.35% | 277B | | +16.00% | 243B | | +8.44% | 205B | | -5.97% | 203B | | +6.19% | 164B |
Other Pharmaceuticals
|